Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature

New targets and compounds from BioCentury’s Distillery

Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more

Seeing ‘meaningful’ medicines in pipeline, the Theravance and pharma vet jumps to a well-funded biotech, taking the reins from a leader he knows well

Australian-German newco is delivering antibody therapies inside liver cells by encoding them as mRNA

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President